APO Research
Talk to an analyst

APO RESEARCH · REPORT

Non-Insulin Hypoglycemic Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Non-Insulin Hypoglycemic Drug Industry Growth and Trends Forecast to 2032

29 December 2025118 pages

Choose your research edition.

Industry ResearchNon-Insulin Hypoglycemic Drug Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Non-Insulin Hypoglycemic Drug Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Non-Insulin Hypoglycemic Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Non-Insulin Hypoglycemic Drug Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Non-Insulin Hypoglycemic Drug Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Non-Insulin Hypoglycemic Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Non-Insulin Hypoglycemic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Non-Insulin Hypoglycemic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Non-Insulin Hypoglycemic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Non-Insulin Hypoglycemic Drug include GSK, Takeda, Merck, Uni-Bio Science Group, Eli Lilly, Jiangsu Hengrui Medicine, Jiangsu Hansoh Pharmaceutical, Pfizer and Sumitomo Dainippon Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Non-Insulin Hypoglycemic Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Non-Insulin Hypoglycemic Drug market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Non-Insulin Hypoglycemic Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Non-Insulin Hypoglycemic Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Non-Insulin Hypoglycemic Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Non-Insulin Hypoglycemic Drug Market by Company

GSK

Takeda

Merck

Uni-Bio Science Group

Eli Lilly

Jiangsu Hengrui Medicine

Jiangsu Hansoh Pharmaceutical

Pfizer

Sumitomo Dainippon Pharma

Servier

Novo Nordisk

Luye Pharma Group

Intarcia Therapeutics

Geropharm

Eurofarma

Emisphere

Dong-A Pharmaceutical

Alkem Labs

3SBio

Non-Insulin Hypoglycemic Drug Segment by Type

Alpha Glucosidase Inhibitors

Meglitinides

Sulfonylureas

Thiazolidinediones

Biguanides

Others

Non-Insulin Hypoglycemic Drug Segment by Application

Hospital Pharmacies

Retail Pharmacies

Non-Insulin Hypoglycemic Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-Insulin Hypoglycemic Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Non-Insulin Hypoglycemic Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-Insulin Hypoglycemic Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Non-Insulin Hypoglycemic Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Non-Insulin Hypoglycemic Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Alpha Glucosidase Inhibitors Table 2. Major Company of Meglitinides Table 3. Major Company of Sulfonylureas Table 4. Major Company of Thiazolidinediones Table 5. Major Company of Biguanides Table 6. Major Company of Others Table 7. Global Non-Insulin Hypoglycemic Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 8. Global Non-Insulin Hypoglycemic Drug Sales by Type (2021-2026) & (K Units) Table 9. Global Non-Insulin Hypoglycemic Drug Sales Market Share in Volume by Type (2021-2026) Table 10. Global Non-Insulin Hypoglycemic Drug Sales by Type (2021-2026) & (US$ Million) Table 11. Global Non-Insulin Hypoglycemic Drug Sales Market Share in Value by Type (2021-2026) Table 12. Global Non-Insulin Hypoglycemic Drug Price by Type (2021-2026) & (US$/Unit) Table 13. Global Non-Insulin Hypoglycemic Drug Sales by Type (2027-2032) & (K Units) Table 14. Global Non-Insulin Hypoglycemic Drug Sales Market Share in Volume by Type (2027-2032) Table 15. Global Non-Insulin Hypoglycemic Drug Sales by Type (2027-2032) & (US$ Million) Table 16. Global Non-Insulin Hypoglycemic Drug Sales Market Share in Value by Type (2027-2032) Table 17. Global Non-Insulin Hypoglycemic Drug Price by Type (2027-2032) & (US$/Unit) Table 18. North America Non-Insulin Hypoglycemic Drug Sales by Type (2021-2026) & (K Units) Table 19. North America Non-Insulin Hypoglycemic Drug Sales by Type (2021-2026) & (US$ Million) Table 20. Europe Non-Insulin Hypoglycemic Drug Sales by Type (2021-2026) & (K Units) Table 21. Europe Non-Insulin Hypoglycemic Drug Sales by Type (2021-2026) & (US$ Million) Table 22. Asia-Pacific Non-Insulin Hypoglycemic Drug Sales by Type (2021-2026) & (K Units) Table 23. Asia-Pacific Non-Insulin Hypoglycemic Drug Sales by Type (2021-2026) & (US$ Million) Table 24. Latin America Non-Insulin Hypoglycemic Drug Sales by Type (2021-2026) & (K Units) Table 25. Latin America Non-Insulin Hypoglycemic Drug Sales by Type (2021-2026) & (US$ Million) Table 26. Middle East and Africa Non-Insulin Hypoglycemic Drug Sales by Type (2021-2026) & (K Units) Table 27. Middle East and Africa Non-Insulin Hypoglycemic Drug Sales by Type (2021-2026) & (US$ Million) Table 28. Non-Insulin Hypoglycemic Drug Industry Trends Table 29. Non-Insulin Hypoglycemic Drug Industry Drivers Table 30. Non-Insulin Hypoglycemic Drug Industry Opportunities and Challenges Table 31. Non-Insulin Hypoglycemic Drug Industry Restraints Table 32. Global Non-Insulin Hypoglycemic Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 33. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Company (2021-2026) Table 34. Global Non-Insulin Hypoglycemic Drug Sales by Company (2021-2026) & (K Units) Table 35. Global Non-Insulin Hypoglycemic Drug Sales Share by Company (2021-2026) Table 36. Global Non-Insulin Hypoglycemic Drug Market Price by Company (2021-2026) & (US$/Unit) Table 37. Global Non-Insulin Hypoglycemic Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 38. Global Non-Insulin Hypoglycemic Drug Major Company Production Sites and Headquarters Table 39. Global Non-Insulin Hypoglycemic Drug Company, Product Type & Application Table 40. Global Non-Insulin Hypoglycemic Drug Company Establishment Date Table 41. Global Company Market Concentration Ratio (CR5 and HHI) Table 42. Global Non-Insulin Hypoglycemic Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 43. Global Non-Insulin Hypoglycemic Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 44. Global Non-Insulin Hypoglycemic Drug Sales by Region (2021-2026) & (K Units) Table 45. Global Non-Insulin Hypoglycemic Drug Sales Market Share in Volume by Region (2021-2026) Table 46. Global Non-Insulin Hypoglycemic Drug Sales by Region (2021-2026) & (US$ Million) Table 47. Global Non-Insulin Hypoglycemic Drug Sales Market Share in Value by Region (2021-2026) Table 48. Global Non-Insulin Hypoglycemic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 49. Global Non-Insulin Hypoglycemic Drug Sales by Region (2027-2032) & (K Units) Table 50. Global Non-Insulin Hypoglycemic Drug Sales Market Share in Volume by Region (2027-2032) Table 51. Global Non-Insulin Hypoglycemic Drug Sales by Region (2027-2032) & (US$ Million) Table 52. Global Non-Insulin Hypoglycemic Drug Sales Market Share in Value by Region (2027-2032) Table 53. Global Non-Insulin Hypoglycemic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 54. Global Non-Insulin Hypoglycemic Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 55. Global Non-Insulin Hypoglycemic Drug Sales by Application (2021-2026) & (K Units) Table 56. Global Non-Insulin Hypoglycemic Drug Sales Market Share in Volume by Application (2021-2026) Table 57. Global Non-Insulin Hypoglycemic Drug Sales by Application (2021-2026) & (US$ Million) Table 58. Global Non-Insulin Hypoglycemic Drug Sales Market Share in Value by Application (2021-2026) Table 59. Global Non-Insulin Hypoglycemic Drug Price by Application (2021-2026) & (US$/Unit) Table 60. Global Non-Insulin Hypoglycemic Drug Sales by Application (2027-2032) & (K Units) Table 61. Global Non-Insulin Hypoglycemic Drug Sales Market Share in Volume by Application (2027-2032) Table 62. Global Non-Insulin Hypoglycemic Drug Sales by Application (2027-2032) & (US$ Million) Table 63. Global Non-Insulin Hypoglycemic Drug Sales Market Share in Value by Application (2027-2032) Table 64. Global Non-Insulin Hypoglycemic Drug Price by Application (2027-2032) & (US$/Unit) Table 65. North America Non-Insulin Hypoglycemic Drug Sales by Application (2021-2026) & (K Units) Table 66. North America Non-Insulin Hypoglycemic Drug Sales by Application (2021-2026) & (US$ Million) Table 67. Europe Non-Insulin Hypoglycemic Drug Sales by Application (2021-2026) & (K Units) Table 68. Europe Non-Insulin Hypoglycemic Drug Sales by Application (2021-2026) & (US$ Million) Table 69. Asia-Pacific Non-Insulin Hypoglycemic Drug Sales by Application (2021-2026) & (K Units) Table 70. Asia-Pacific Non-Insulin Hypoglycemic Drug Sales by Application (2021-2026) & (US$ Million) Table 71. Latin America Non-Insulin Hypoglycemic Drug Sales by Application (2021-2026) & (K Units) Table 72. Latin America Non-Insulin Hypoglycemic Drug Sales by Application (2021-2026) & (US$ Million) Table 73. Middle East and Africa Non-Insulin Hypoglycemic Drug Sales by Application (2021-2026) & (K Units) Table 74. Middle East and Africa Non-Insulin Hypoglycemic Drug Sales by Application (2021-2026) & (US$ Million) Table 75. GSK Company Information Table 76. GSK Business Overview Table 77. GSK Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. GSK Non-Insulin Hypoglycemic Drug Product Portfolio Table 79. GSK Recent Development Table 80. Takeda Company Information Table 81. Takeda Business Overview Table 82. Takeda Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Takeda Non-Insulin Hypoglycemic Drug Product Portfolio Table 84. Takeda Recent Development Table 85. Merck Company Information Table 86. Merck Business Overview Table 87. Merck Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Merck Non-Insulin Hypoglycemic Drug Product Portfolio Table 89. Merck Recent Development Table 90. Uni-Bio Science Group Company Information Table 91. Uni-Bio Science Group Business Overview Table 92. Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Product Portfolio Table 94. Uni-Bio Science Group Recent Development Table 95. Eli Lilly Company Information Table 96. Eli Lilly Business Overview Table 97. Eli Lilly Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Eli Lilly Non-Insulin Hypoglycemic Drug Product Portfolio Table 99. Eli Lilly Recent Development Table 100. Jiangsu Hengrui Medicine Company Information Table 101. Jiangsu Hengrui Medicine Business Overview Table 102. Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Product Portfolio Table 104. Jiangsu Hengrui Medicine Recent Development Table 105. Jiangsu Hansoh Pharmaceutical Company Information Table 106. Jiangsu Hansoh Pharmaceutical Business Overview Table 107. Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Product Portfolio Table 109. Jiangsu Hansoh Pharmaceutical Recent Development Table 110. Pfizer Company Information Table 111. Pfizer Business Overview Table 112. Pfizer Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Pfizer Non-Insulin Hypoglycemic Drug Product Portfolio Table 114. Pfizer Recent Development Table 115. Sumitomo Dainippon Pharma Company Information Table 116. Sumitomo Dainippon Pharma Business Overview Table 117. Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Product Portfolio Table 119. Sumitomo Dainippon Pharma Recent Development Table 120. Servier Company Information Table 121. Servier Business Overview Table 122. Servier Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Servier Non-Insulin Hypoglycemic Drug Product Portfolio Table 124. Servier Recent Development Table 125. Novo Nordisk Company Information Table 126. Novo Nordisk Business Overview Table 127. Novo Nordisk Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Novo Nordisk Non-Insulin Hypoglycemic Drug Product Portfolio Table 129. Novo Nordisk Recent Development Table 130. Luye Pharma Group Company Information Table 131. Luye Pharma Group Business Overview Table 132. Luye Pharma Group Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Luye Pharma Group Non-Insulin Hypoglycemic Drug Product Portfolio Table 134. Luye Pharma Group Recent Development Table 135. Intarcia Therapeutics Company Information Table 136. Intarcia Therapeutics Business Overview Table 137. Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Product Portfolio Table 139. Intarcia Therapeutics Recent Development Table 140. Geropharm Company Information Table 141. Geropharm Business Overview Table 142. Geropharm Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. Geropharm Non-Insulin Hypoglycemic Drug Product Portfolio Table 144. Geropharm Recent Development Table 145. Eurofarma Company Information Table 146. Eurofarma Business Overview Table 147. Eurofarma Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 148. Eurofarma Non-Insulin Hypoglycemic Drug Product Portfolio Table 149. Eurofarma Recent Development Table 150. Emisphere Company Information Table 151. Emisphere Business Overview Table 152. Emisphere Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 153. Emisphere Non-Insulin Hypoglycemic Drug Product Portfolio Table 154. Emisphere Recent Development Table 155. Dong-A Pharmaceutical Company Information Table 156. Dong-A Pharmaceutical Business Overview Table 157. Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 158. Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Product Portfolio Table 159. Dong-A Pharmaceutical Recent Development Table 160. Alkem Labs Company Information Table 161. Alkem Labs Business Overview Table 162. Alkem Labs Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 163. Alkem Labs Non-Insulin Hypoglycemic Drug Product Portfolio Table 164. Alkem Labs Recent Development Table 165. 3SBio Company Information Table 166. 3SBio Business Overview Table 167. 3SBio Non-Insulin Hypoglycemic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 168. 3SBio Non-Insulin Hypoglycemic Drug Product Portfolio Table 169. 3SBio Recent Development Table 170. North America Non-Insulin Hypoglycemic Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 171. North America Non-Insulin Hypoglycemic Drug Sales by Country (2021-2026) & (K Units) Table 172. North America Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2021-2026) Table 173. North America Non-Insulin Hypoglycemic Drug Sales Forecast by Country (2027-2032) & (K Units) Table 174. North America Non-Insulin Hypoglycemic Drug Sales Market Share Forecast by Country (2027-2032) Table 175. North America Non-Insulin Hypoglycemic Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 176. North America Non-Insulin Hypoglycemic Drug Market Size by Country (2021-2026) & (US$ Million) Table 177. North America Non-Insulin Hypoglycemic Drug Market Share by Country (2021-2026) Table 178. North America Non-Insulin Hypoglycemic Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 179. North America Non-Insulin Hypoglycemic Drug Market Share Forecast by Country (2027-2032) Table 180. Europe Non-Insulin Hypoglycemic Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 181. Europe Non-Insulin Hypoglycemic Drug Sales by Country (2021-2026) & (K Units) Table 182. Europe Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2021-2026) Table 183. Europe Non-Insulin Hypoglycemic Drug Sales Forecast by Country (2027-2032) & (K Units) Table 184. Europe Non-Insulin Hypoglycemic Drug Sales Market Share Forecast by Country (2027-2032) Table 185. Europe Non-Insulin Hypoglycemic Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 186. Europe Non-Insulin Hypoglycemic Drug Market Size by Country (2021-2026) & (US$ Million) Table 187. Europe Non-Insulin Hypoglycemic Drug Market Share by Country (2021-2026) Table 188. Europe Non-Insulin Hypoglycemic Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 189. Europe Non-Insulin Hypoglycemic Drug Market Share Forecast by Country (2027-2032) Table 190. Asia-Pacific Non-Insulin Hypoglycemic Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 191. Asia-Pacific Non-Insulin Hypoglycemic Drug Sales by Country (2021-2026) & (K Units) Table 192. Asia-Pacific Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2021-2026) Table 193. Asia-Pacific Non-Insulin Hypoglycemic Drug Sales Forecast by Country (2027-2032) & (K Units) Table 194. Asia-Pacific Non-Insulin Hypoglycemic Drug Sales Market Share Forecast by Country (2027-2032) Table 195. Asia-Pacific Non-Insulin Hypoglycemic Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 196. Asia-Pacific Non-Insulin Hypoglycemic Drug Market Size by Country (2021-2026) & (US$ Million) Table 197. Asia-Pacific Non-Insulin Hypoglycemic Drug Market Share by Country (2021-2026) Table 198. Asia-Pacific Non-Insulin Hypoglycemic Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 199. Asia-Pacific Non-Insulin Hypoglycemic Drug Market Share Forecast by Country (2027-2032) Table 200. Latin America Non-Insulin Hypoglycemic Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 201. Latin America Non-Insulin Hypoglycemic Drug Sales by Country (2021-2026) & (K Units) Table 202. Latin America Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2021-2026) Table 203. Latin America Non-Insulin Hypoglycemic Drug Sales Forecast by Country (2027-2032) & (K Units) Table 204. Latin America Non-Insulin Hypoglycemic Drug Sales Market Share Forecast by Country (2027-2032) Table 205. Latin America Non-Insulin Hypoglycemic Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 206. Latin America Non-Insulin Hypoglycemic Drug Market Size by Country (2021-2026) & (US$ Million) Table 207. Latin America Non-Insulin Hypoglycemic Drug Market Share by Country (2021-2026) Table 208. Latin America Non-Insulin Hypoglycemic Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 209. Latin America Non-Insulin Hypoglycemic Drug Market Share Forecast by Country (2027-2032) Table 210. Middle East and Africa Non-Insulin Hypoglycemic Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 211. Middle East and Africa Non-Insulin Hypoglycemic Drug Sales by Country (2021-2026) & (K Units) Table 212. Middle East and Africa Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2021-2026) Table 213. Middle East and Africa Non-Insulin Hypoglycemic Drug Sales Forecast by Country (2027-2032) & (K Units) Table 214. Middle East and Africa Non-Insulin Hypoglycemic Drug Sales Market Share Forecast by Country (2027-2032) Table 215. Middle East and Africa Non-Insulin Hypoglycemic Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 216. Middle East and Africa Non-Insulin Hypoglycemic Drug Market Size by Country (2021-2026) & (US$ Million) Table 217. Middle East and Africa Non-Insulin Hypoglycemic Drug Market Share by Country (2021-2026) Table 218. Middle East and Africa Non-Insulin Hypoglycemic Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 219. Middle East and Africa Non-Insulin Hypoglycemic Drug Market Share Forecast by Country (2027-2032) Table 220. Key Raw Materials Table 221. Raw Materials Key Suppliers Table 222. Non-Insulin Hypoglycemic Drug Distributors List Table 223. Non-Insulin Hypoglycemic Drug Customers List Table 224. Research Programs/Design for This Report Table 225. Authors List of This Report Table 226. Secondary Sources Table 227. Primary Sources List of Figures Figure 1. Non-Insulin Hypoglycemic Drug Image Figure 2. Global Non-Insulin Hypoglycemic Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Non-Insulin Hypoglycemic Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Non-Insulin Hypoglycemic Drug Sales (2021-2032) & (K Units) Figure 5. Alpha Glucosidase Inhibitors Image Figure 6. Global Alpha Glucosidase Inhibitors Sales YoY Growth (2021-2032) & (K Units) Figure 7. Meglitinides Image Figure 8. Global Meglitinides Sales YoY Growth (2021-2032) & (K Units) Figure 9. Sulfonylureas Image Figure 10. Global Sulfonylureas Sales YoY Growth (2021-2032) & (K Units) Figure 11. Thiazolidinediones Image Figure 12. Global Thiazolidinediones Sales YoY Growth (2021-2032) & (K Units) Figure 13. Biguanides Image Figure 14. Global Biguanides Sales YoY Growth (2021-2032) & (K Units) Figure 15. Others Image Figure 16. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 17. Global Non-Insulin Hypoglycemic Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 18. Global Non-Insulin Hypoglycemic Drug Market Share by Type 2025 VS 2032 Figure 19. North America Non-Insulin Hypoglycemic Drug Sales Market Share in Volume by Type in 2025 Figure 20. North America Non-Insulin Hypoglycemic Drug Sales Market Share in Value by Type in 2025 Figure 21. Europe Non-Insulin Hypoglycemic Drug Sales Market Share in Volume by Type in 2025 Figure 22. Europe Non-Insulin Hypoglycemic Drug Sales Market Share in Value by Type in 2025 Figure 23. Asia-Pacific Non-Insulin Hypoglycemic Drug Sales Market Share in Volume by Type in 2025 Figure 24. Asia-Pacific Non-Insulin Hypoglycemic Drug Sales Market Share in Value by Type in 2025 Figure 25. Latin America Non-Insulin Hypoglycemic Drug Sales Market Share in Volume by Type in 2025 Figure 26. Latin America Non-Insulin Hypoglycemic Drug Sales Market Share in Value by Type in 2025 Figure 27. Middle East and Africa Non-Insulin Hypoglycemic Drug Sales Market Share in Volume by Type in 2025 Figure 28. Middle East and Africa Non-Insulin Hypoglycemic Drug Sales Market Share in Value by Type in 2025 Figure 29. Global Top 5 and 10 Non-Insulin Hypoglycemic Drug Players Market Share by Revenue in 2025 Figure 30. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Hospital Pharmacies Image Figure 32. Global Hospital Pharmacies Sales YoY Growth (2021-2032) & (K Units) Figure 33. Retail Pharmacies Image Figure 34. Global Retail Pharmacies Sales YoY Growth (2021-2032) & (K Units) Figure 35. Global Non-Insulin Hypoglycemic Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Non-Insulin Hypoglycemic Drug Market Share by Application 2025 VS 2032 Figure 37. North America Non-Insulin Hypoglycemic Drug Sales Market Share in Volume by Application in 2025 Figure 38. North America Non-Insulin Hypoglycemic Drug Sales Market Share in Value by Application in 2025 Figure 39. Europe Non-Insulin Hypoglycemic Drug Sales Market Share in Volume by Application in 2025 Figure 40. Europe Non-Insulin Hypoglycemic Drug Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific Non-Insulin Hypoglycemic Drug Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific Non-Insulin Hypoglycemic Drug Sales Market Share in Value by Application in 2025 Figure 43. Latin America Non-Insulin Hypoglycemic Drug Sales Market Share in Volume by Application in 2025 Figure 44. Latin America Non-Insulin Hypoglycemic Drug Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa Non-Insulin Hypoglycemic Drug Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa Non-Insulin Hypoglycemic Drug Sales Market Share in Value by Application in 2025 Figure 47. North America Non-Insulin Hypoglycemic Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. North America Non-Insulin Hypoglycemic Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America Non-Insulin Hypoglycemic Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America Non-Insulin Hypoglycemic Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Non-Insulin Hypoglycemic Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Europe Non-Insulin Hypoglycemic Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Non-Insulin Hypoglycemic Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe Non-Insulin Hypoglycemic Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Non-Insulin Hypoglycemic Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Asia-Pacific Non-Insulin Hypoglycemic Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Non-Insulin Hypoglycemic Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific Non-Insulin Hypoglycemic Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Non-Insulin Hypoglycemic Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Latin America Non-Insulin Hypoglycemic Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Non-Insulin Hypoglycemic Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America Non-Insulin Hypoglycemic Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Non-Insulin Hypoglycemic Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Middle East and Africa Non-Insulin Hypoglycemic Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Non-Insulin Hypoglycemic Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa Non-Insulin Hypoglycemic Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Non-Insulin Hypoglycemic Drug Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. Non-Insulin Hypoglycemic Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Alpha Glucosidase Inhibitors
  • Meglitinides
  • Sulfonylureas
  • Thiazolidinediones
  • Biguanides
  • Others
Applications
  • Hospital Pharmacies
  • Retail Pharmacies
Companies covered
  • GSK
  • Takeda
  • Merck
  • Uni-Bio Science Group
  • Eli Lilly
  • Jiangsu Hengrui Medicine
  • Jiangsu Hansoh Pharmaceutical
  • Pfizer
  • Sumitomo Dainippon Pharma
  • Servier
  • Novo Nordisk
  • Luye Pharma Group
  • Intarcia Therapeutics
  • Geropharm
  • Eurofarma
  • Emisphere
  • Dong-A Pharmaceutical
  • Alkem Labs
  • 3SBio

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Non-Insulin Hypoglycemic Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Non-Insulin Hypoglycemic Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Non-Insulin Hypoglycemic Drug Market by Type
  6. 1.3.1 Alpha Glucosidase Inhibitors
  7. 1.3.2 Meglitinides
  8. 1.3.3 Sulfonylureas
  9. 1.3.4 Thiazolidinediones
  10. 1.3.5 Biguanides
  11. 1.3.6 Others
  12. 1.4 Global Non-Insulin Hypoglycemic Drug Market Size by Type
  13. 1.4.1 Global Non-Insulin Hypoglycemic Drug Market Size Overview by Type (2021-2032)
  14. 1.4.2 Global Non-Insulin Hypoglycemic Drug Historic Market Size Review by Type (2021-2026)
  15. 1.4.3 Global Non-Insulin Hypoglycemic Drug Forecasted Market Size by Type (2027-2032)
  16. 1.5 Key Regions Market Size by Type
  17. 1.5.1 North America Non-Insulin Hypoglycemic Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.2 Europe Non-Insulin Hypoglycemic Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.3 Asia-Pacific Non-Insulin Hypoglycemic Drug Sales Breakdown by Type (2021-2026)
  20. 1.5.4 South America Non-Insulin Hypoglycemic Drug Sales Breakdown by Type (2021-2026)
  21. 1.5.5 Middle East and Africa Non-Insulin Hypoglycemic Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Non-Insulin Hypoglycemic Drug Industry Trends
  2. 2.2 Non-Insulin Hypoglycemic Drug Industry Drivers
  3. 2.3 Non-Insulin Hypoglycemic Drug Industry Opportunities and Challenges
  4. 2.4 Non-Insulin Hypoglycemic Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Non-Insulin Hypoglycemic Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Non-Insulin Hypoglycemic Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Non-Insulin Hypoglycemic Drug Price (2021-2026)
  4. 3.4 Global Non-Insulin Hypoglycemic Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Non-Insulin Hypoglycemic Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Non-Insulin Hypoglycemic Drug Company, Product Type & Application
  7. 3.7 Global Non-Insulin Hypoglycemic Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Non-Insulin Hypoglycemic Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Non-Insulin Hypoglycemic Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Non-Insulin Hypoglycemic Drug Tier 1, Tier 2, and Tier 3
4 Non-Insulin Hypoglycemic Drug Regional Status and Outlook
  1. 4.1 Global Non-Insulin Hypoglycemic Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Non-Insulin Hypoglycemic Drug Historic Market Size by Region
  3. 4.2.1 Global Non-Insulin Hypoglycemic Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Non-Insulin Hypoglycemic Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Non-Insulin Hypoglycemic Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Non-Insulin Hypoglycemic Drug Forecasted Market Size by Region
  7. 4.3.1 Global Non-Insulin Hypoglycemic Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Non-Insulin Hypoglycemic Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Non-Insulin Hypoglycemic Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Non-Insulin Hypoglycemic Drug by Application
  1. 5.1 Non-Insulin Hypoglycemic Drug Market by Application
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Retail Pharmacies
  4. 5.2 Global Non-Insulin Hypoglycemic Drug Market Size by Application
  5. 5.2.1 Global Non-Insulin Hypoglycemic Drug Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Non-Insulin Hypoglycemic Drug Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Non-Insulin Hypoglycemic Drug Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Non-Insulin Hypoglycemic Drug Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Non-Insulin Hypoglycemic Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Non-Insulin Hypoglycemic Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Non-Insulin Hypoglycemic Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Non-Insulin Hypoglycemic Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 GSK
  2. 6.1.1 GSK Company Information
  3. 6.1.2 GSK Business Overview
  4. 6.1.3 GSK Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 GSK Non-Insulin Hypoglycemic Drug Product Portfolio
  6. 6.1.5 GSK Recent Developments
  7. 6.2 Takeda
  8. 6.2.1 Takeda Company Information
  9. 6.2.2 Takeda Business Overview
  10. 6.2.3 Takeda Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Takeda Non-Insulin Hypoglycemic Drug Product Portfolio
  12. 6.2.5 Takeda Recent Developments
  13. 6.3 Merck
  14. 6.3.1 Merck Company Information
  15. 6.3.2 Merck Business Overview
  16. 6.3.3 Merck Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Merck Non-Insulin Hypoglycemic Drug Product Portfolio
  18. 6.3.5 Merck Recent Developments
  19. 6.4 Uni-Bio Science Group
  20. 6.4.1 Uni-Bio Science Group Company Information
  21. 6.4.2 Uni-Bio Science Group Business Overview
  22. 6.4.3 Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Product Portfolio
  24. 6.4.5 Uni-Bio Science Group Recent Developments
  25. 6.5 Eli Lilly
  26. 6.5.1 Eli Lilly Company Information
  27. 6.5.2 Eli Lilly Business Overview
  28. 6.5.3 Eli Lilly Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Eli Lilly Non-Insulin Hypoglycemic Drug Product Portfolio
  30. 6.5.5 Eli Lilly Recent Developments
  31. 6.6 Jiangsu Hengrui Medicine
  32. 6.6.1 Jiangsu Hengrui Medicine Company Information
  33. 6.6.2 Jiangsu Hengrui Medicine Business Overview
  34. 6.6.3 Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Product Portfolio
  36. 6.6.5 Jiangsu Hengrui Medicine Recent Developments
  37. 6.7 Jiangsu Hansoh Pharmaceutical
  38. 6.7.1 Jiangsu Hansoh Pharmaceutical Company Information
  39. 6.7.2 Jiangsu Hansoh Pharmaceutical Business Overview
  40. 6.7.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Product Portfolio
  42. 6.7.5 Jiangsu Hansoh Pharmaceutical Recent Developments
  43. 6.8 Pfizer
  44. 6.8.1 Pfizer Company Information
  45. 6.8.2 Pfizer Business Overview
  46. 6.8.3 Pfizer Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Pfizer Non-Insulin Hypoglycemic Drug Product Portfolio
  48. 6.8.5 Pfizer Recent Developments
  49. 6.9 Sumitomo Dainippon Pharma
  50. 6.9.1 Sumitomo Dainippon Pharma Company Information
  51. 6.9.2 Sumitomo Dainippon Pharma Business Overview
  52. 6.9.3 Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Product Portfolio
  54. 6.9.5 Sumitomo Dainippon Pharma Recent Developments
  55. 6.10 Servier
  56. 6.10.1 Servier Company Information
  57. 6.10.2 Servier Business Overview
  58. 6.10.3 Servier Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Servier Non-Insulin Hypoglycemic Drug Product Portfolio
  60. 6.10.5 Servier Recent Developments
  61. 6.11 Novo Nordisk
  62. 6.11.1 Novo Nordisk Company Information
  63. 6.11.2 Novo Nordisk Business Overview
  64. 6.11.3 Novo Nordisk Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Novo Nordisk Non-Insulin Hypoglycemic Drug Product Portfolio
  66. 6.11.5 Novo Nordisk Recent Developments
  67. 6.12 Luye Pharma Group
  68. 6.12.1 Luye Pharma Group Company Information
  69. 6.12.2 Luye Pharma Group Business Overview
  70. 6.12.3 Luye Pharma Group Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Luye Pharma Group Non-Insulin Hypoglycemic Drug Product Portfolio
  72. 6.12.5 Luye Pharma Group Recent Developments
  73. 6.13 Intarcia Therapeutics
  74. 6.13.1 Intarcia Therapeutics Company Information
  75. 6.13.2 Intarcia Therapeutics Business Overview
  76. 6.13.3 Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Product Portfolio
  78. 6.13.5 Intarcia Therapeutics Recent Developments
  79. 6.14 Geropharm
  80. 6.14.1 Geropharm Company Information
  81. 6.14.2 Geropharm Business Overview
  82. 6.14.3 Geropharm Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Geropharm Non-Insulin Hypoglycemic Drug Product Portfolio
  84. 6.14.5 Geropharm Recent Developments
  85. 6.15 Eurofarma
  86. 6.15.1 Eurofarma Company Information
  87. 6.15.2 Eurofarma Business Overview
  88. 6.15.3 Eurofarma Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Eurofarma Non-Insulin Hypoglycemic Drug Product Portfolio
  90. 6.15.5 Eurofarma Recent Developments
  91. 6.16 Emisphere
  92. 6.16.1 Emisphere Company Information
  93. 6.16.2 Emisphere Business Overview
  94. 6.16.3 Emisphere Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Emisphere Non-Insulin Hypoglycemic Drug Product Portfolio
  96. 6.16.5 Emisphere Recent Developments
  97. 6.17 Dong-A Pharmaceutical
  98. 6.17.1 Dong-A Pharmaceutical Company Information
  99. 6.17.2 Dong-A Pharmaceutical Business Overview
  100. 6.17.3 Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Product Portfolio
  102. 6.17.5 Dong-A Pharmaceutical Recent Developments
  103. 6.18 Alkem Labs
  104. 6.18.1 Alkem Labs Company Information
  105. 6.18.2 Alkem Labs Business Overview
  106. 6.18.3 Alkem Labs Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Alkem Labs Non-Insulin Hypoglycemic Drug Product Portfolio
  108. 6.18.5 Alkem Labs Recent Developments
  109. 6.19 3SBio
  110. 6.19.1 3SBio Company Information
  111. 6.19.2 3SBio Business Overview
  112. 6.19.3 3SBio Non-Insulin Hypoglycemic Drug Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 3SBio Non-Insulin Hypoglycemic Drug Product Portfolio
  114. 6.19.5 3SBio Recent Developments
7 North America by Country
  1. 7.1 North America Non-Insulin Hypoglycemic Drug Sales by Country
  2. 7.1.1 North America Non-Insulin Hypoglycemic Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Non-Insulin Hypoglycemic Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Non-Insulin Hypoglycemic Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Non-Insulin Hypoglycemic Drug Market Size by Country
  6. 7.2.1 North America Non-Insulin Hypoglycemic Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Non-Insulin Hypoglycemic Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Non-Insulin Hypoglycemic Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Non-Insulin Hypoglycemic Drug Sales by Country
  2. 8.1.1 Europe Non-Insulin Hypoglycemic Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Non-Insulin Hypoglycemic Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Non-Insulin Hypoglycemic Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Non-Insulin Hypoglycemic Drug Market Size by Country
  6. 8.2.1 Europe Non-Insulin Hypoglycemic Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Non-Insulin Hypoglycemic Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Non-Insulin Hypoglycemic Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Non-Insulin Hypoglycemic Drug Sales by Country
  2. 9.1.1 Asia-Pacific Non-Insulin Hypoglycemic Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Non-Insulin Hypoglycemic Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Non-Insulin Hypoglycemic Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Non-Insulin Hypoglycemic Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Non-Insulin Hypoglycemic Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Non-Insulin Hypoglycemic Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Non-Insulin Hypoglycemic Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Non-Insulin Hypoglycemic Drug Sales by Country
  2. 10.1.1 South America Non-Insulin Hypoglycemic Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Non-Insulin Hypoglycemic Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Non-Insulin Hypoglycemic Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Non-Insulin Hypoglycemic Drug Market Size by Country
  6. 10.2.1 South America Non-Insulin Hypoglycemic Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Non-Insulin Hypoglycemic Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Non-Insulin Hypoglycemic Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Non-Insulin Hypoglycemic Drug Sales by Country
  2. 11.1.1 Middle East and Africa Non-Insulin Hypoglycemic Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Non-Insulin Hypoglycemic Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Non-Insulin Hypoglycemic Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Non-Insulin Hypoglycemic Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Non-Insulin Hypoglycemic Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Non-Insulin Hypoglycemic Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Non-Insulin Hypoglycemic Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Non-Insulin Hypoglycemic Drug Value Chain Analysis
  2. 12.1.1 Non-Insulin Hypoglycemic Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Non-Insulin Hypoglycemic Drug Production Mode & Process
  7. 12.2 Non-Insulin Hypoglycemic Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Non-Insulin Hypoglycemic Drug Distributors
  10. 12.2.3 Non-Insulin Hypoglycemic Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst